Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor ...

J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.

Congruence Therapeutics has completed a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.

The streamlined framework is part of the UK Government’s plans to ensure the life sciences sector reaches its full potential.

Quintessence's technology is designed to simplify the bio-separation process in CGT manufacturing while reducing production costs.

An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...

Peter Fassler, Director Market Access at Gilead Sciences, highlighted the challenges facing the Netherlands and the rest of Europe in ensuring access to innovation therapies, at the Advanced Therapies ...

Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six pipeline TCE therapies.

At Advanced Therapies, investors noted that early planning, adaptability and building trust will help a biotech startup succeed.

R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in CKD ...

The FDA has issued a CRL to Aldeyra Therapeutics for its new drug application (NDA) of reproxalap to treat dry eye disease.